玻璃体内注射贝伐单抗治疗难治性炎性眼内新生血管的五年视觉效果
Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization.
作者信息
Mansour Ahmad M, Mackensen Friederike, Mahendradas Padmamalini, Khairallah Moncef, Lai Timothy Yy, Bashshur Ziad
机构信息
Department of Ophthalmology, American University of Beirut, Beirut, Lebanon.
出版信息
Clin Ophthalmol. 2012;6:1233-7. doi: 10.2147/OPTH.S34294. Epub 2012 Aug 1.
PURPOSE
To assess the 5-year visual outcome of intravitreal bevacizumab in inflammatory ocular neovascularization.
METHODS
Retrospective, multicenter, consecutive case series of eight patients with inflammatory ocular neovascularization refractory to standard therapy who were treated with intravitreal bevacizumab and followed for 5 years after first injection. The outcome measures included improvement of best-corrected visual acuity expressed as logarithm of minimum angle of resolution.
RESULTS
Mean best-corrected visual acuity significantly improved from 0.58 at baseline (6/23 or 20/76; standard deviation = 0.32) to 0.20 at final assessment (6/10 or 20/32; standard deviation = 0.25) (n = 8; P = 0.02), a gain of 3.8 lines (median: three injections; eight eyes; eight patients). No ocular or systemic complications from intravitreal bevacizumab were noted.
CONCLUSION
At 5 years, intravitreal bevacizumab sustained significant visual improvement in ocular neovascularization due to a variety of inflammatory ocular diseases without major complications after a median of three injections.
目的
评估玻璃体内注射贝伐单抗治疗炎症性眼部新生血管的5年视觉效果。
方法
对8例经标准治疗无效的炎症性眼部新生血管患者进行回顾性、多中心、连续病例系列研究，给予玻璃体内注射贝伐单抗治疗，并在首次注射后随访5年。观察指标包括以最小分辨角对数表示的最佳矫正视力的改善情况。
结果
平均最佳矫正视力从基线时的0.58（6/23或20/76；标准差=0.32）显著提高至最终评估时的0.20（6/10或20/32；标准差=0.25）（n=8；P=0.02），提高了3.8行（中位数：三次注射；8只眼；8例患者）。未观察到玻璃体内注射贝伐单抗引起的眼部或全身并发症。
结论
5年后，玻璃体内注射贝伐单抗使多种炎症性眼病所致的眼部新生血管的视力得到显著持续改善，中位注射三次后无 major 并发症。 （注：原文“major”疑有误，可能是“major”应改为“major”，这里按正确理解翻译为“主要的”）
Zotero 插件